Manipal Health confirms KFin as Registrar and Share Transfer Agent

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights

Manipal Health Enterprises Limited appointed KFin Technologies Limited as its Registrar and Share Transfer Agent effective February 13, 2025. The move complies with SEBI LODR Regulation 7(1). The filing was submitted on August 5, 2026.

powered bylight_fuzz_icon
47465520

*this image is generated using AI for illustrative purposes only.

Manipal Health Enterprises Limited has confirmed the appointment of KFin Technologies Limited as its Registrar and Share Transfer Agent (R&SA). The appointment, effective from February 13, 2025, ensures compliance with Regulation 7(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This structural update standardizes share transfer processes for investors.

The company disclosed this appointment in a filing dated August 5, 2026, submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE). The disclosure was made under Regulation 7(1) of the SEBI LODR Regulations, 2015, which mandates timely intimation of changes in R&SA appointments to ensure transparency and operational continuity for shareholders.

KFin Technologies Limited, headquartered at 301, The Centrium, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Mumbai, Maharashtra, India, 400 070, continues to act in this capacity. The firm handles critical investor services including share transfers, transmission of shares, and maintenance of the register of members.

The filing was signed by Sathish K R, Company Secretary and Compliance Officer of Manipal Health Enterprises Limited, bearing Membership No. A15203. The digital signature timestamp indicates the submission occurred on August 5, 2026, at 11:31:54 IST.

Key Details

Parameter Detail
Appointed R&SA KFin Technologies Limited
Effective Date February 13, 2025
Regulatory Basis SEBI LODR Regulation 7(1), 2015
Filing Date August 5, 2026
Authorized Signatory Sathish K R (Company Secretary)

This appointment aligns with standard corporate governance practices for listed entities in India, ensuring that shareholder records are maintained by a specialized agency approved by regulatory standards.

Historical Stock Returns for Manipal Health Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
+4.22%+9.69%0.0%0.0%0.0%0.0%

How might the six-month delay between the effective date and the public filing impact investor confidence in Manipal Health's corporate governance transparency?

What operational efficiencies or cost savings does Manipal Health Enterprises expect to realize by standardizing share transfer processes through KFin Technologies?

Are there any pending shareholder disputes or transmission issues that this R&SA appointment aims to resolve or streamline?

Manipal Health Enterprises
View Company Insights
View All News
like16
dislike

Manipal Health Enterprises adopts SEBI fair disclosure code for UPSI

scanx
Reviewed by
Riya DScanX News Team
Key Highlights

Manipal Health Enterprises Limited has implemented a comprehensive Code of Practices for fair disclosure of Unpublished Price Sensitive Information under SEBI PIT Regulations. The framework assigns responsibilities to the CIRO and Compliance Officer to ensure prompt, uniform dissemination of material data. It includes strict protocols for analyst interactions, handling market rumors, and sharing information for legitimate business purposes, with a mandatory eight-year digital record retention. The policy takes effect upon Board approval of the Draft Red Herring Prospectus.

powered bylight_fuzz_icon
47463944

*this image is generated using AI for illustrative purposes only.

Manipal Health Enterprises Limited has adopted a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) to comply with Regulation 8(1) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The filing, submitted to the BSE and NSE on August 5, 2026, outlines a framework designed to ensure uniformity, transparency, and fairness in dealings with all stakeholders while preventing selective disclosure of material events. The adoption of this Code is a procedural requirement preceding the company’s public listing, ensuring that price-sensitive information is disseminated promptly and universally to maintain market integrity.

The Code designates specific roles for oversight, including a Chief Investor Relations Officer (CIRO) and a Compliance Officer. The CIRO is responsible for ensuring the uniform dissemination of information, monitoring compliance with disclosure timelines, and assessing the materiality of information in consultation with senior management. The Compliance Officer oversees the maintenance of records, monitors adherence to UPSI preservation rules, and ensures timely reporting of shareholding changes. Both officers work together to review disclosure controls and educate employees on regulatory requirements.

Key Provisions of the Disclosure Framework

The Code establishes strict protocols for handling Unpublished Price Sensitive Information to avoid selective disclosure. Key operational guidelines include:

Provision Area Requirement
Prompt Disclosure UPSI must be disclosed to Stock Exchanges and posted on the company website as soon as credible information arises.
Selective Disclosure If information is disclosed selectively or inadvertently, it must be made generally available through exchanges and the website immediately.
Analyst Interactions No UPSI may be shared with analysts unless simultaneously made public; transcripts of calls must be recorded and disclosed.
Legitimate Purpose Sharing UPSI for genuine business purposes requires wall-crossing procedures, confidentiality agreements, and recipient identification.
Digital Database A structured digital database with audit trails must be maintained for at least eight years post-transaction.

The policy emphasizes that any inadvertent leakage of information triggers an immediate obligation to make that information generally available. The CIRO must consult the CEO, Whole-time Director, or CFO before responding to queries regarding market rumors, ensuring that all public announcements are accurate and compliant with SEBI’s Listing Obligations and Disclosure Requirements Regulations, 2015.

Handling Legitimate Business Purposes

Recognizing that UPSI may need to be shared for legitimate business purposes, the Code defines “legitimate purpose” to include sharing information with partners, lenders, auditors, legal advisors, and regulators in the ordinary course of business. Such sharing is permitted only if it does not evade insider trading prohibitions. Recipients of UPSI must sign confidentiality agreements acknowledging their status as insiders and agreeing not to trade in the company’s securities while in possession of such information. The Company must obtain detailed identifiers, including PAN numbers, for all recipients and maintain a structured digital database of these interactions.

Effective Date and Regulatory Context

The Code becomes effective from the date of approval of the Draft Red Herring Prospectus by the Board. This timing aligns with the company’s transition towards public listing, where rigorous disclosure standards are mandatory. The Board reserves the right to review and amend the Code to remain consistent with evolving statutory and regulatory directions. The submission of this Code under Regulation 8(2) of the PIT Regulations serves as formal intimation to the stock exchanges, ensuring that the regulatory framework for fair disclosure is in place before the commencement of public trading.

Historical Stock Returns for Manipal Health Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
+4.22%+9.69%0.0%0.0%0.0%0.0%

How might the strict implementation of this disclosure framework impact Manipal Health Enterprises' valuation during its upcoming IPO?

What are the potential risks of insider trading violations if the digital audit trail system fails to capture informal communications effectively?

Could the requirement for immediate public disclosure of inadvertent leaks create volatility in the stock price during the initial trading period?

Manipal Health Enterprises
View Company Insights
View All News
like18
dislike
1 Year Returns:0.00%